About Doctor PT-141

What this desk is

Doctor PT-141 reads the peer-reviewed research and the approved label on PT-141 (bremelanotide) and grades what it finds — strong claims marked strong, weak ones marked weak. No clinic stands behind it: there are no clinicians on staff, nothing here is medical advice, and there is no product to make, stock, or sell. The whole of the work is a cited reading of published science.

The site is built as a trust-and-evidence console: a place where the central mechanism, the RECONNECT trials, the FDA label figures, and the documented tolerability record are laid out plainly and cited, so a reader can see at a glance how strong — and how bounded — each claim is.

What 'Doctor' means here

The word 'Doctor' in the domain sets a register — careful, reference-grade, verifiable — not a description of services. It reads the way a trustworthy medical-information source reads; it does not mean the site diagnoses, treats, prescribes, or consults. No doctors, pharmacists, or clinical staff sit behind this page, and no prescription, treatment, or consultation is on offer. PT-141 is a prescription drug for its approved indication, and decisions about it belong with a qualified clinician, not a website.

How we handle evidence

Every clinical number here is tied to a source in the references. We mark the difference between approved and off-label use, between human trials and animal models, and between cited evidence and unverified community reports. Where the evidence is strong — the two Phase 3 RECONNECT trials, the 52-week extension, the fMRI mechanism study — we say so. Where it is modest, disputed, or early-phase — the small effect sizes, the 2023 Expression of Concern on a 2008 study, the investigational male data — we say that too. The honest record includes its own limitations, and we keep those in plain view rather than smoothing them over.